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Intravenous (IV) levetiracetam (LEV) is currently approved as an alternative or replacement
therapy for patients unable to take the oral form of this antiepileptic drug (AED). The oral
form has Food and Drug Administration (FDA) indications for adjunctive therapy in the treat-
ment of partial onset epilepsy ages 1 month or more, myoclonic seizures associated with
juvenile myoclonic epilepsy starting with the age of 12 and primary generalized tonic-clonic
seizures in people 6 years and older. Since the initial introduction, oral and IV LEV has been
evaluated in various studies conducted in the critical care setting for the treatment of sta-
tus epilepticus, stroke-related seizures, seizures following subarachnoid or intracerebral
hemorrhage, post-traumatic seizures, tumor-related seizures, and seizures in critically ill
patients. Additionally, studies evaluating rapid infusion of IV LEV and therapeutic monitor-
ing of serum LEV levels in different patient populations have been performed. In this review
we present the current state of knowledge on LEV use in the critical care setting focusing
on the IV uses and discuss future research needs.
Keywords: intravenous levetiracetam, status epilepticus, pediatric population, stroke-related seizures,
post-traumatic seizures, loading dose, therapeutic monitoring
INTRODUCTION
Currently, intravenous (IV) levetiracetam (LEV) is approved only
as an alternative or replacement therapy for patients unable to take
the oral form of this antiepileptic drug (AED). The oral form of
LEV is also approved for use in patients with multiple types of
seizures and epilepsies. But, this AED has been increasingly used
in the critical care setting (e.g., emergency rooms or intensive care
units) due to its relative ease of use, positive outcomes, and the
low side effects profile which are thought to be better than some
of the other commonly used in this setting AEDs, e.g., pheny-
toin (PHT) (1, 2). When it was introduced to the market, LEV
was marketed as an AED with a novel structure and mechanism
of action – its main mechanism of action is modulating neuro-
transmitter release via binding to the synaptic vesicle protein 2A
and, thus, via inhibiting calcium release from intracellular stores.
Other mechanisms of action include opposition of the negative
modulation of gammabutyric acid (GABA-) and glycine-gated
currents, inhibition of the neuronal synchronization and of the
N-type calcium channels (3). Oral LEV is rapidly and almost com-
pletely absorbed with plasma peak concentration reached within
1 h of intake but food can delay and reduce the peak concentration
without an effect on bioavailability (4). In ICU patients who have
received LEV for seizure prophylaxis (500 mg every 12 h) the clear-
ance of LEV was faster when compared to the similar values obtain
in healthy controls and patients in status epilepticus (SE); Monte
Carlo simulation determined the most optimal LEV doses in these
patients to achieve appropriate serum concentration should be
either 1,000 mg every 8 h or 1,500–2,000 mg every 12 h (5). In
patients with or without preexisting epilepsy who presented with
SE and who were taking between none and several concomitant
AEDs the pharmacokinetic data of IV infusion were comparable
to the previously published values derived from healthy volunteers
(6) while doses of IV LEV that were antiepileptogenic in animal
models of epilepsy (55 mg/kg/day) administered to patients with
traumatic brain injury (TBI) resulted in comparable pharmaco-
kinetics (PK) in children, adults, and elderly with similar results
observed between days 3 and 30 of treatment (delay in T max in
elderly was observed but this was of unclear clinical significance)
(7). One study in patients with subarachnoid hemorrhage (SAH)
compared the plasma concentrations of LEV while receiving IV
or parenteral forms for seizure prevention – when switched to
parenteral form the levels decreased to 70% of the IV levels but
complications in response to this change were not observed (8).
Finally, LEV is known to suppress seizures in the animal models of
epilepsy and pretreatment with LEV can delay or altogether pre-
vent the development of kindled seizures (9–12). Thus, the overall
very favorable clinical and pharmacokinetic profiles make LEV a
desirable treatment option for the use in the critical care setting.
The goal for this invited commentary was to review the available
literature focusing on the use of LEV in the critical care setting and
to provide recommendations for future research.
MATERIALS AND METHODS
An extensive literature search was performed evaluating studies for
IV LEV use in critical setting for the management of SE in adults,
stroke-related seizures,TBI,SAH, intracranial hemorrhage, seizure
prophylaxis in patients undergoing surgery for brain tumors and
its use in neonates, and children and blood levels and therapeutic
monitoring.
RESULTS
SPECIAL PATIENT POPULATIONS
Status epilepticus
The initial reports of the use of LEV in the setting of SE utilized oral
doses administered via feeding tube in patients ages 16–91 years.
One study reported complete seizure control in all patients within
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12–96 h of the initial LEV administration and the other study
reported good outcomes in 11/13 episodes of SE (13, 14). Since
then and since the IV form of LEV became available in 2006, this
AED has been frequently favored in the critical care setting over
other AEDs because of the simplicity of administration, linear PK,
lack of significant cardiovascular side effects and lack of interac-
tions with other medications (1, 3). This includes the use of IV LEV
for the treatment of all types of seizures and SE. Four open-label
prospective clinical studies evaluated use of IV LEV in adults with
convulsive SE and found IV LEV to be effective in terminating SE
with minimal side effects (6, 15–17). In the first study, Fattouch et
al. used LEV as first-line therapy to demonstrate resolution or sig-
nificant reduction in SE and seizures in 8/9 elderly patients who
had no seizure recurrence within 24 h and who did not report
any adverse events (16). The study by Misra et al. randomized 79
patients with seizures lasting >5 min to an initial therapy with
IV LEV 20 mg/kg over 15 min or IV lorazepam (LZP) 0.1 mg/kg
over 2–4 min with switch-over in case of lack of efficacy (17).
This study demonstrated similar efficacy for the treatment of SE
between LEV (29/38; 76.3%) vs. LZP (31/41; 75.6%); after switch-
over 88.9% were controlled with LZP vs. 70% with LEV. The 24-h
seizure-free rate was 23/29 for LEV and 21/31 for LZP. However,
LZP patients experienced a higher need of artificial ventilation
(17). In another study, Uges et al. determined that IV LEV added
to standard SE treatment [IV clonazepam and/or rectal diazepam
followed as needed by PHT or valproic acid (VPA)], was feasible
and safe (6). Finally, in the study by Eue et al. 43 patients with
SE were treated with IV LEV 1,000 or 2,000 mg after treatment
with benzodiazepines was deemed to be ineffective. IV LEV was
well tolerated and terminated SE in 19/43 patients; LEV was more
effective in simple focal, complex focal, and myoclonic SE than in
non-convulsive, subtle, or secondarily generalized SE (0/8) (15).
Several retrospective studies of IV LEV for the treatment of
various forms of SE were conducted in 236 adults (18–22). For
example, one study found that LEV was effective in controlling
SE in 57.5% of patients with higher chance of seizure control
if used as initial therapy or add-on to benzodiazepines (BZD;
78.5%) than as an add-on to treatment (BZD plus PHT, VPA,
or both; 46.1%) (18). A study by Alvarez et al. compared ben-
zodiazepines plus second-line treatment with PHT, VPA, or LEV
to find LEV to be less effective in controlling SE than VPA at
51.7 vs. 74.6% but there were no differences in outcomes at dis-
charge between the three groups (19). Another study by Möddel
et al. found that IV LEV (bolus or continuous infusion) resolved
refractory SE in 69% of 36 patients; higher incidence of failures
was associated with doses>3,000 mg/day, lack of bolus, treatment
initiated>48 h after diagnosis, non-convulsive SE with coma, peri-
odic lateralized epileptiform transients, acute cerebral lesion, and
intubation narcosis (21). Overall, these studies used variable doses
of LEV between 1,000 and 9,000 mg/day with or without ini-
tial bolus. Of importance, these studies reported low numbers
of patients with side effects due to LEV which typically included
nausea and vomiting (20, 21), elevated liver enzymes (20), and
transient thrombocytopenia (22). The reported mortality was 17%
(responders 4%, non-responders 45%) (21). The message from
these prospective and retrospective data collections appears to be
fairly clear – the efficacy of IV LEV for the management of SE
appears to be between 48 and 94% (probably closer to 50%) with
better efficacy reported with early LEV initiation and with pre-
treatment with BDZ as seen in studies of other AEDs in animal
and human SE (23, 24).
Stroke-related seizures
The American Stroke Association’s guidelines for early manage-
ment of adults with ischemic stroke state that prophylactic use
of AEDs in patients with stroke who have not had seizures is not
recommended (Class III, Level of Evidence C); but, if seizures
after stroke occur, treatment should follow the guidelines for the
management of seizures in other neurological conditions (Class
I, Level of Evidence B) (25). Overall, three studies reported on
treating 98 patients with post-stroke seizures with LEV (ages 57–
89 years) (26–28). In one prospective study, 82.4% of patients were
seizure-free on LEV doses ranging from 1,000 to 2,000 mg/day
(27). Another study, reported on the treatment of early and late
seizures in the setting of ischemic or hemorrhagic stroke and found
that in∼90% of patients seizures were controlled (26/29) with LEV
dosed at 1,000–2,000 mg/day (28). Finally, Belcastro et al. treated
35 post-stroke seizure patients with LEV to report seizure free-
dom of 77.1% (26). Additional retrospective studies evaluated the
efficacy of LEV in a total of 92 patients with early or late post-
stroke seizures in doses of up to 3,000 mg/day (29–31). In either
monotherapy or adjunctive therapy, in the majority of patients
seizures were controlled. While the incidence of early and late
seizures in patients with stroke (ischemic or hemorrhagic) is fairly
high, reaching in some studies 10% or more (32, 33), and many
calls made for the development of randomized controlled trials
for seizure treatment or seizure prevention in these patients, such
studies have not been conducted to date (34).
Post-traumatic seizures
According to the published guidelines, the prophylactic use of PHT
may reduce early post-traumatic seizures (within 7 days; Class I)
but this or other AEDs are not recommended for preventing late
post-traumatic seizures (>7 days of injury; Class I) (35, 36). One
open-label, non-randomized phase II study compared prophylac-
tic LEV for 30 days (N = 66) to no AED use (observation; N = 60)
in 86 adults and 40 children following TBI (37). Patients with
early presentation (within 8 h of TBI) received LEV while patients
presenting >8 h after TBI did not receive LEV. The severity of
TBI was higher in the LEV-treated group (p= 0.03). This study
reported seizure incidence of 10.9% in the treated group (more
severe TBI group) vs. 20% in the observation group at 2 years
but the difference was not significant (p= 0.18) (37). Two-year
follow-up of the pediatric group (N = 40) revealed that only one
patient developed late seizures/epilepsy (defined as seizures after
the initial 7 days period) (38).
Several prospective studies of seizure prevention in adults
following TBI focused on the use of LEV up to the dose of
4,000 mg/day. Szaflarski et al. in a prospective, single-blinded,
randomized clinical trial compared LEV to PHT within 24 h of
TBI or SAH in 52 patients (39). While there were no differences
in seizure or mortality outcomes between the groups, patients
dosed with LEV had better outcomes including lower Disabil-
ity Rating Scale (DRS) scores at 3 months and higher Glasgow
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Outcomes Scale at 6 months when compared to patients treated
with PHT. In this study, seizure incidence was based on the results
of video/EEG monitoring conducted for up to 72 h after the ini-
tial dose of AED was administered which is considered standard
in the setting of severe TBI (40). In another prospective non-
randomized and not blinded study, Inaba et al. evaluated 813
patients with blunt TBI who were treated prophylactically with
LEV (N = 406) or PHT (N = 407) and then monitored for the
development for clinical seizures (no EEG monitoring) within
7 days (41). Further, patient distribution in the treatment arms
was unbalanced with each center following local practice patterns
and one of the centers preferentially utilizing LEV and the other
PHT. Results demonstrated no differences in mortality (5.4 vs.
3.7%, p= 0.236), seizure rate (1.5 vs. 1.5%, p= 0.997), or adverse
drug reactions (7.9 vs. 10.3%, p= 0.227) between the two groups.
Jones et al. prospectively evaluated 32 patients who had received
LEV for seizure prevention in the setting of severe TBI and com-
pared them to 41 patients treated with PHT (42). While only some
patients in each group received EEG, increased “seizure tendency”
on EEG was observed in patients who have received LEV when
compared to PHT (p= 0.003); seizure incidence between groups
was similar (p= 0.556). In another report, 6/7 patients with post-
traumatic epilepsy became seizure-free after initiation of add-on
therapy with LEV but only a relatively short (10–16 months)
follow-up period was reported (43). Adverse outcomes reported
in these studies included headache, somnolence, memory impair-
ment, irritability, dizziness, depression, and ataxia with some of the
studies reporting higher incidence of adverse outcomes in patients
receiving PHT (39, 41, 42).
Approximately 30% of the use of LEV in the critical care
setting is for seizure prophylaxis in patients with TBI (1) but
the data to support such use are incomplete. Randomized and
double-blinded studies are needed to address this unmet need
and to provide unambiguous data regarding the short- and long-
term outcomes (seizures/epilepsy, cognitive, quality of life, etc.) in
patients with TBI.
Seizures following subarachnoid or intracerebral hemorrhage
The published guidelines recommend prophylactic anticonvul-
sant use in the immediate post-hemorrhagic period in patients
with aneurysmal SAH (Class IIb, Level of Evidence B) but dis-
courage routine long-term use of anticonvulsants (Class III, Level
of Evidence B) (44, 45). Prospective studies in this population
include one that compared IV LEV (N = 18) to IV VPA (N = 17)
and demonstrated no difference in seizure occurrence between the
groups and no adverse effects in the group using LEV (8). In a con-
venience sample of 442 consecutive patients with SAH (N = 297
treated before ICU protocol change with IV PHT load followed
by 14 days of PHT treatment with doses adjusted based on the
presence of low levels or seizures and N = 145 treated with IV
LEV 500 mg twice daily without loading dose for 3 days after pro-
tocol change) Murphy-Human et al. found no difference in early
seizures, mortality rate, and intensive care unit or total hospital
stay in patients with SAH. There was an increased likelihood of
late seizures (≥3 days post-SAH) and in-hospital seizures in the
LEV group. However, the significant differences in treatment pat-
tern between AEDs in this study (lack of loading and much shorter
treatment with LEV) make the comparison of efficacy for seizure
prevention between the groups difficult which the authors rec-
ognize as a shortcoming (46). A prospective observational study
in patients with intracerebral hemorrhage (ICH) found similar
risk of seizures between patients who had received PHT (N = 28)
and LEV (N = 18) for seizure prevention (p> 0.1) but patients
treated with PHT fared overall worse with increased risk of poor
outcome (p= 0.02) and more adverse events of treatment; (47)
these results have confirmed their previous findings of poorer out-
comes in patients with SAH treated for seizure prophylaxis with
PHT (48).
A retrospective study of the prophylactic use of PHT (N = 25;
loading dose 15–20 mg/kg with later adjustments of the dose)
or LEV (N = 60; dose 500–2,000 mg/day) in patients with ICH
(N = 40), SAH (N = 26) or subdural hemorrhage (SDH; N = 19)
found patients treated with LEV to have higher Glasgow Coma
Scale (GCS) scores at discharge, lower seizure incidence, and
higher percentage discharge home when compared to the PHT
group (2). Trend toward better cognitive outcomes in the LEV
group was also observed (p= 0.08). Shah and Husain retrospec-
tively evaluated 176 patients with post-aneurysmal SAH who
received prophylactic treatment with PHT (loading dose 20 mg/kg
and maintenance dose 5–7 mg/kg/day) who were later transitioned
to LEV (1,500 mg twice daily) due to adverse events including ele-
vated transaminases, thrombocytopenia, rash, unexplained fever,
mental status decline, or gastrointestinal (GI) disturbance; all but
one patient switched to LEV with GI disturbance and three patients
with mental status abnormalities had subsequent improvement or
resolution of symptoms at discharge or by the first follow-up visit
(14–41 days following discharge). Adverse events occurred more
frequently in the PHT group and there were no clinical seizures in
the LEV group (49).
Tumor-related seizures
It should not be a surprise to note LEV being used in the set-
ting of seizure prevention or seizure treatment in patients with
central nervous system (CNS) malignancies – several early studies
reported positive experiences in this setting (50, 51). The main
reason for this switch in practice pattern is the fact that the newer
AEDs (including LEV) do not interfere with the metabolism of
chemotherapeutics and, thus, do not negatively affect their effi-
cacy (52). Overall, seizures/epilepsy is common in patients with
brain malignancies ranging from ∼10% in patients with CNS
lymphomas and up to 100% in dysembryoplastic tumors (53).
Generally, initiation of therapy with an AED is warranted in
patients who had at least one seizure in the setting of a brain
tumor but whether an AED should be initiated in patients with
brain tumors who have not experienced a seizure is less clear.
Depending on type of tumor, age, location, etc., patients diag-
nosed with CNS malignancies have 20–45% chance of develop-
ing seizures (53). Some authorities suggest the use of LEV or
gabapentin as first-line therapy for the treatment of seizures in
patients with brain tumors (54). One of the first LEV studies
in this population enrolled 26 patients with gliomas – LEV was
used as an add-on therapy from 2,000 to 4,000 mg/day to achieve
seizure reduction of >50% in 65% of the patients (4/20 previ-
ously refractory patients became seizure-free) (51). A prospective
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observational study enrolled 30 patients with brain tumors and
epilepsy who were treated with LEV administered for 4 weeks prior
to and for 4 weeks following respective procedure (N = 25 for the
post-surgical group) (55). Initial doses were 1,000 mg/day with
dose escalation in case of seizures up to 3,000 mg/day. Of the 25
patients, 88% were seizure-free at 48 h and 84% were seizure-free
at 4 weeks following surgery (55). Another prospective open-label
study evaluated treatment with LEV monotherapy for the first
post-resection month in 17 patients with brain tumors who had
>1 seizure within 1 month prior to surgery (56). Postoperatively,
all patients received IV LEV for 48 h at 500 mg BID or pre-surgery
dose, then titrated up by 500 mg/day to goal 3,000 mg/day as toler-
ated. There was a >50% reduction in seizures in 11/12 patients
who completed the study. Lim et al. conducted a prospective,
open-label study of transition from monotherapy with PHT to
monotherapy with LEV in 29 patients for postoperative control
of glioma-related seizures (1/3 continued on PHT while 2/3 tran-
sitioned to LEV) (57). At 6 months after surgery, 87% (13/15)
of patients on LEV and 75% (6/8) of patients on PHT were
seizure-free. Both groups had similar incidence of excessive sleepi-
ness, sleeping difficulty, and lack of energy or strength, although
increased incoordination in PHT group and increased slurred
speech in LEV group.
Finally, Milligan and colleagues performed a retrospective
analysis on the incidence of early seizures and postoperative
epilepsy in 315 adults following supratentorial surgery who
received prophylactic monotherapy LEV (500–3,000 mg/day) vs.
monotherapy PHT (200–800 mg/day). Ninety-nine patients had a
primary brain tumor and in those patients, early seizures occurred
in 2.3% on LEV and 3.6% on PHT. Fifty-five of the 99 patients
were followed >12 months and 5/11 on LEV and 24/44 on PHT
developed epilepsy. Thirty-eight patients on PHT vs. one patient
on LEV discontinued AED treatment due to side effects (p= 0.03)
(58). Another retrospective study evaluated prophylactic use of
LEV (1,000–3,000 mg/day) in 78 patients with supratentorial brain
tumors. Preoperative seizure incidence was 38.5% and postopera-
tive seizures occurred in 2.6% (2/78) patients with 91% of patients
being seizure-free at the end of the mean follow-up to 10.5 months
(59). Finally, Hildebrand et al. reported on the use of various AEDs
in the setting of brain tumors including LEV to find epilepsy in
80% of their patients; the typical dose was 1,000–3,000 mg/day
but the treatment of LEV was not compared specifically to other
AEDs (60).
While substantial body of evidence is available regarding the
treatment of seizures in the setting of brain tumors or supratento-
rial surgery for the management of brain tumors and some have
advocated the use of LEV in this setting after the data by Milli-
gan et al. were published (58, 61), careful prospective studies are
needed to assess the use of LEV as a preventive AED in this setting,
to evaluate complex interaction between surgery, chemotherapy,
and AEDs and, finally, whether LEV should be the preferred AED
in this setting instead of PHT or VPA (53, 54).
Geriatric population
There were no observed safety differences between 347 geriatric
patients (age≥ 65) and younger patients treated with LEV for
seizures, although the number of the elderly patients enrolled
in the controlled trials of epilepsy is insufficient to determine
the effectiveness of LEV in this population [package insert (62)].
Nevertheless, geriatric patients have been enrolled in many of the
retrospective and prospective studies of LEV including studies that
used IV doses of LEV. For example, Uges et al. analyzed safety and
PK of IV infusion of LEV in patients with SE ages 44–75 years
of age (median 60 years) to show PK values in the studied group
similar to norms obtained from healthy (and younger) volunteers
(6). Another study by Klein et al. showed that T max was longer
in subjects older than 65 years of age when compared to children
and young adults at the initiation of the therapy and at 30 days
(7). In the elderly LEV appears to be safe and associated with a
relatively low level of adverse events. In part, this is related to
lack of significant drug–drug interactions. Overall, PK studies and
safety/efficacy studies of LEV in the elderly are needed as the inci-
dence and prevalence of epilepsy, and thus the use of AEDs in this
population are increasing.
The use of IV LEV in the pediatric population
When initially approved by the FDA, IV LEV was not indicated
for use in children less than 16 years of age. Since then, prospec-
tive studies using IV LEV to treat acute seizures in neonates and
children have assessed the safety and efficacy of LEV use in these
age groups (63, 64). Ramantani et al. conducted a prospective
feasibility study in 38 newborns with LEV applied as first-line
treatment for EEG-confirmed seizures (64). In this study the
initial IV dose was 10 mg/kg with gradual increase up to 45–
60 mg/kg over 7 days; 30/38 infants were seizure-free at the end
of the evaluation period (22 had to receive additional doses of
phenobarbital). Another study evaluated a single dose of IV LEV
50 mg/kg infused over 15 min in 30 children (mean age 6.3 years;
range 6 months to 14.8 years) diagnosed with epilepsy (29/30)
or a single seizure related to a brain lesion. The mean blood
level 10 min after infusion was 83.3 mcg/mL (47–128 mcg/mL);
administration of LEV was associated with a subsequent reduc-
tion of all seizure types for up to 24-h after the infusion (63).
Adverse events in both studies included sleepiness and/or fatigue,
drowsiness with titration, and thrombocytopenia with concur-
rent VPA use. Further studies utilizing IV LEV for the treatment
of acute seizures in 189 pediatric patients (1 day to 18 years) in
eight retrospective case series and two case reports resulted an
improved clinical seizure control; 118/189 reported concurrent
EEG monitoring which demonstrated improved electrographic
seizure control (65–74).
METHODS OF INFUSION AND MONITORING
Rapid infusion
Intravenous LEV is supplied in a concentrated form that needs to
be diluted in compatible diluent prior to administration. While
the IV formulation is reported to be bioequivalent to the oral
formulation and doses should be interchangeable some differ-
ences in bioavailability between the IV and parenteral doses have
been reported (8). There are also some age-related differences in
PK (7) but it is unclear whether these differences are of clinical
significance. In one study, Wheless et al. assessed rapid infusion
(over 5–6 min) of 20, 40, and 60 mg/kg (N = 15 per group) of
IV LEV in children and adults (4–32 years of age). Maximum
Frontiers in Neurology | Epilepsy August 2013 | Volume 4 | Article 121 | 4
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DeWolfe and Szaflarski LEV in ICU
plasma concentration peaked 15 min after infusion. The infu-
sion was well tolerated with minimal side effects including non-
pruritic rash (N = 1) and infusion site pain (N = 2); there were
no electrocardiographic changes reported (75).
Therapeutic monitoring of serum LEV levels in different patient
populations
Although therapeutic serum concentration ranges and a sched-
ule for blood level monitoring for LEV have not been established,
monitoring is recommended, e.g., from pregnancy through the
postpartum period due to physiologic changes leading to gradual
decreases in LEV plasma levels with the advancement of the preg-
nancy (62). One prospective study in 30 epilepsy patients on >2
AEDs, including LEV in doses ranging from 2,000 to 3,000 mg/day,
defined the therapeutic LEV plasma range of 10–40 mcg/mL (76).
Eighteen patients were either seizure-free (N = 5) or had >50%
seizure reduction (N = 13). The majority of patients had an asso-
ciated therapeutic LEV range in the low-therapeutic range. In
patients with LEV level within the low-therapeutic range adjust-
ments in dose produced either further therapeutic response or
allowed for the patients to be weaned from one of the other
AEDs without any ill effects. Another study in 297 inpatients using
LEV in doses 250–7,000 mg/day demonstrated serum concentra-
tions 1.5–48.2 mcg/mL with the level to dose ratio (LDR) lower in
LEV monotherapy compared to concurrent use of enzyme induc-
ing AEDs (77). In this study, the median LDR was significantly
lower when patients were co-medicated with enzyme inducer (e.g.,
PHT, carbamazepine, or oxcarbazepine) when compared to LEV
monotherapy whereas the LDR of patients co-medicated with
VPA or lamotrigine did not differ significantly from the LDR of
LEV of patients on LEV monotherapy (p> 0.05); children had
lower LEV concentrations than adults on the same dose per body
weight (77).
In a pooled analysis of LEV levels in 1,023 patients enrolled
in four Phase III double-blind trials and during which patients
receiving one to three concomitant AEDs were treated with LEV
(N = 672) or placebo (N = 351) as adjunctive therapy to treat
seizures (78–81), LEV concentrations were normalized to a dose of
1 mg/kg twice daily with mean plasma concentration at 1 h rang-
ing between 1.74 and 2.27µg/mL at 1,000–4,000 mg/day and a
mean plasma LEV level concentration of 2.09µg/mL (95% CI 1.99,
2.19) (82). The mean plasma LEV concentration at 12 h ranged
from 0.7 to 0.88µg/mL at 1,000–4,000 mg/day and a mean plasma
LEV level concentration of 0.82µg/mL (95% CI 0.19, 0.85). LEV
concentrations were lower (<25% on average) in patients using
concurrent enzyme inducing AEDs and moderately higher in
patients using concurrent VPA (12 h post-dose). Two retrospec-
tive studies in 73 adults with epilepsy reported LEV doses ranging
from 1,000 to 4,000 mg/day with therapeutic plasma concentra-
tions between 6 and 65µg/mL (83, 84). Adverse events leading
to LEV discontinuation included behavioral changes (N = 3), gait
disturbance (N = 1), and depression (N = 1) (83, 84). Two ret-
rospective studies in pediatric patients reported LEV doses in 93
children ranging from 12.7 to 84 mg/kg/day with blood levels in
responders ranging from 5 to 60µg/mL (85, 86). None of these
pediatric and adult studies reported dose – level – seizure response
relationship.
Neurocritical care patients
In a prospective open-label, steady-state pharmacokinetic study
12 adults admitted to the neurocritical care unit with SAH, SDH,
or TBI were treated prophylactically with IV LEV (5). Doses of
1,000 mg every 8 h and 1500–2000 mg every 12 h were most likely
to achieve trough levels between 6 and 20µg/mL than doses of
500 mg twice daily; these critically ill patients demonstrated faster
systemic clearance and shorter terminal elimination half-life com-
pared to previously published data on healthy volunteers and
adults in SE. Another prospective single-center registry in 35 crit-
ically ill patients with aneurysmal SAH reported decreased LEV
plasma concentrations after transition from IV to parenteral dose
with concurrent decrease in bioavailability by∼30% (8).
SUMMARY
Intravenous LEV is a safe and effective treatment for acute seizures
and SE and has fewer side effects than some traditional first-
line agents. The evidence suggests that early treatment and use
in focal and myoclonic SE may be more effective than in secondar-
ily generalized SE. However, large controlled and blinded studies
are needed to answer these questions. Most studies in patients
with SAH or ICH demonstrated no difference in early seizures or
mortality with prophylactic use of LEV when compared to other
AEDs. Only one prospective study suggested increased rate of late
seizures in patients on LEV compared to PHT, however IV for-
mulation was changed to enteral formulation and it is unclear
how that may have affected the outcome; the treatment with LEV
in this study was overall shorter and the LEV dose substantially
lower than the dose of the comparator – PHT which may have
affected the results. Several studies in patients with SAH, ICH, or
TBI found decreased side effects in patients on LEV vs. PHT or
VPA. There was no difference in rate of post-traumatic seizures
or mortality in patients with TBI whether treated with LEV or
PHT, however reduced disability scores at 3 months and higher
Glasgow Outcomes Scale scores at 6 months in patients on LEV
suggest a potential neuroprotective effect of LEV which is in agree-
ment with animal studies. IV LEV has proven to be effective and
safe for use in treating acute seizures in children of all ages from
premature neonates to teenagers. Rapid infusion of IV LEV over
5 min in children and adults is safe and well tolerated. Therapeutic
LEV monitoring is important to perform in some patient popula-
tions, especially in those who are critically ill, but the relationship
between the dose – level – seizure response has not been estab-
lished. Neurocritical care patients may have increased clearance
with a shorter half-life compared to patients who are healthy or in
SE patients.
FUTURE DIRECTIONS
The above presented data collected prospectively or retrospec-
tively support further studies of the use of LEV in the setting of
CNS emergencies whether for seizure prevention/treatment or for
assessing the short- and long-term cognitive and societal outcomes
(e.g., employment, quality of life, etc.). Further, randomized and
double-blind studies of acute seizures and SE across ages appear
to be warranted. Long-term neurological functional and disabil-
ity status outcomes after administering IV LEV within 24 h of TBI
should be performed to confirm the neuroprotective effects of LEV
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observed in animal studies. Further studies should be performed
to evaluate effective doses of LEV in critically ill patients and
determine optimal schedule for therapeutic monitoring. Although
some studies suggest IV LEV is safe and tolerable in geriatric
patients, larger prospective studies are needed to determine the
efficacy in this population, including potentially decreased renal
function.
KEY CONCEPTS
1. Intravenous LEV is effective in terminating many types of
seizures and SE, including convulsive SE and partial SE and
is well tolerated with minimal side effects unlike some typical
first and second-line agents.
2. In patients with TBI or intracranial hemorrhage long-term
prophylaxis with LEV vs. PHT may not alter the incidence of
seizures or mortality, however, patients treated with LEV may
have better long-term outcomes.
3. In prospective and retrospective studies IV LEV appears to be
a safe and effective treatment for acute seizures in premature
and term newborns, school-aged children, and teenagers.
4. IV LEV can be infused rapidly over 5 min with maximal
peak concentration in 15 min without significant clinical or
electrocardiographic side effects in children and adults.
5. Critical care patients may have faster systemic clearance and
shorter terminal elimination half-life of IV LEV compared to
previously published data on healthy volunteers and adults in
SE. Conversion to enteral formulation in these patients may
result in lower plasma concentrations. Serum level monitoring
should be considered in critically ill patients though the clinical
importance of the monitoring is not clear.
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